International phase IV field study for the reliability and validity of the European Organisation for Research and Treatment of Cancer Thyroid Cancer Module EORTC QLQ-THY34

Singer, S; Al-Ibraheem, A; Pinto, M; Iakovou, I; Østhus, AA; Hammerlid, E; Locati, LD; Gamper, E; Ignacio, J; Jordan, SJ; Kiyota, N; Buettner, M; Engesser, D; Canotilho, R; Ioannidis, G; Husson, O; Gama, RR; Fanetti, G; Moss, L; Inhestern, J; Andry, G; Fuehrer, D; Kuliś, D; Rimmele, H; Sykiotis, G

doi:10.1089/thy.2023.0221

Endocrine oncology

International phase IV field study for the reliability and validity of the European Organisation for Research and Treatment of Cancer Thyroid Cancer Module EORTC QLQ-THY34

ThyroidPublished 14 Jul 2023Validation study

Read the original article ↗PubMed

Cite

Authors' conclusion

The EORTC QLQ-THY34 with its 9 multi-item and 8 single-item scales is a reliable and valid tool to measure quality of life in thyroid cancer patients and can be used in future trials and studies.

Study context

Population: Thyroid cancer patients from 17 countries
Participants: 437 patients17 countries

Comparison: Group 1 vs Group 2
Group 1n = 303
Group 2n = 134
Outcome: Reliability and validity of the EORTC QLQ-THY34: internal consistency (Cronbach's alpha), scale structure (confirmatory factor analysis), discriminant validity (known-group comparisons), responsiveness and test-retest reliability (ICC)

Methodological detailsinternational, phase IV field study

International
Phase IV field study

Performance

As reported in the abstract

Psychometric properties of EORTC QLQ-THY34

Items fulfilling criteria to be kept in the questionnaire

All 34

Multi-item scales with Cronbach's alpha >0.70

8 of the 9

Reference

Authors: Singer S, Al-Ibraheem A, Pinto M, Iakovou I, Østhus AA, Hammerlid E, et al.
All 25 authors
Singer S, Al-Ibraheem A, Pinto M, Iakovou I, Østhus AA, Hammerlid E, Locati LD, Gamper E, Ignacio J, Jordan SJ, Kiyota N, Buettner M, Engesser D, Canotilho R, Ioannidis G, Husson O, Gama RR, Fanetti G, Moss L, Inhestern J, Andry G, Fuehrer D, Kuliś D, Rimmele H, Sykiotis G
Journal: Thyroid
Published: 14 Jul 2023
DOI: 10.1089/thy.2023.0221
PubMed: 37450344

Topic: Endocrine oncology

Diagnostic definitions

Group 1: undergoing treatment or best supportive care; questionnaires before therapy (t1), 6 weeks later (t2) and 6 months after t2 (t3)
Group 2: survivors ≥2 years after diagnosis; random baseline and 1 week later

Key notes

All standardized factor loadings exceeded 0.40, confirming the proposed scale structure
Intra-class correlations (ICC) >0.70 in all scales (good test-retest reliability)

More notes

Differences in scale scores between patients with different histology >5 points in all scales
Changes over time ≥|4| points between at least two time points in all but one pre-specified scale (Dry Mouth)

Original publication

International phase IV field study for the reliability and validity of the European Organisation for Research and Treatment of Cancer Thyroid Cancer Module EORTC QLQ-THY34. Thyroid. Published 14 July 2023. doi:10.1089/thy.2023.0221

Read the original article ↗

Composed by AI from the published abstract and checked against it. How Briefs are made →